1NKEMIA Logo

1NKEMIA

A tech group providing R&D, services, training, and investment for life sciences industries.

IKM | BME Growth

Overview

Corporate Details

ISIN(s):
ES0156303002
LEI:
959800QRRHKJ6C8MW495
Country:
Spain
Address:
C/Alvarez de Castro 63, 08100 Mollet del Vallès
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

1NKEMIA IUCT Group S.A., founded in 1997, is a technology group focused on the generation and commercial exploitation of knowledge for the life sciences sector. The company provides open R&D, technological services, and training to the chemical, pharmaceutical, biotechnological, cosmetic, and nutraceutical industries. Functioning as a business incubator and investment vehicle, 1NKEMIA actively acquires and holds stakes in high-tech SMEs. The group also manages the 'Fondo Capital Conocimiento' (Knowledge Capital Fund) to foster entrepreneurship and support the development of innovative technologies and startups.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all 1NKEMIA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for 1NKEMIA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for 1NKEMIA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-26 Björn Zethraeus Other Other 6,646 66,460,000.00 SEK
2025-05-24 Anders Nilsson Other Other 10,000 326,900.00 SEK
2025-05-23 marius balger Other Sell 45,000 534,150.00 SEK
2025-05-23 Todd Heringer Other Other 150,000 N/A
2025-05-22 Klaudija Cavala Other Other 100,000 22,000.00 SEK
2025-05-20 Gionata La Torre Other Buy 31,182 951,051.00 SEK
2025-05-20 Karl-Emil Engström Other Sell 5,000 279,350.00 SEK
2025-05-20 Christina Thérèse Hersch Fagerberg Other Sell 1,000 55,870.00 SEK
2025-05-20 Gionata La Torre Other Buy 31,182 N/A
2025-05-19 Erik Gjötterberg Other Other 15,000 311,550.00 SEK

Peer Companies

Keros Therapeutics, Inc. Logo
United States of America
KROS
Kura Oncology, Inc. Logo
Develops targeted precision medicines for high-need cancers like leukemia, head & neck, and lung cancer.
United States of America
KURA
Larimar Therapeutics, Inc. Logo
Clinical-stage biotech developing protein therapies for rare diseases like Friedreich's ataxia.
United States of America
LRMR
Lexaria Bioscience Corp. Logo
Biotech firm with patented technology improving oral drug delivery and absorption.
United States of America
LEXX
LigaChem Biosciences Inc. Logo
Advancing a next-gen ADC platform to develop innovative medicines for unmet needs.
South Korea
141080
Linical Co., Ltd. Logo
Global CRO providing full-service drug development support for biopharma companies.
Japan
2183
Lipigon Pharmaceuticals AB Logo
Develops novel drugs for lipid metabolism disorders to reduce cardiovascular disease risk.
Sweden
LPGO
Lipum AB Logo
Develops first-in-class antibody treatments for chronic inflammatory diseases like arthritis.
Sweden
LIPUM
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
United States of America
RENB

Talk to a Data Expert

Have a question? We'll get back to you promptly.